West Pharmaceutical Services, Inc. (WST) Given New $112.00 Price Target at Wells Fargo & Company

West Pharmaceutical Services, Inc. (NYSE:WST) had its price target lifted by Wells Fargo & Company from $105.00 to $112.00 in a research note issued to investors on Friday, October 27th. They currently have an outperform rating on the medical instruments supplier’s stock.

WST has been the subject of a number of other research reports. Stephens assumed coverage on shares of West Pharmaceutical Services in a report on Tuesday, October 3rd. They issued an equal weight rating and a $99.00 target price for the company. Zacks Investment Research cut shares of West Pharmaceutical Services from a buy rating to a hold rating in a report on Tuesday, July 4th. BidaskClub downgraded West Pharmaceutical Services from a hold rating to a sell rating in a research note on Thursday, July 27th. Bank of America Corporation downgraded West Pharmaceutical Services from a buy rating to a neutral rating and set a $98.00 price objective for the company. in a research note on Tuesday, October 17th. Finally, Jefferies Group LLC raised West Pharmaceutical Services from a hold rating to a buy rating and upped their price objective for the company from $96.00 to $115.00 in a research note on Friday, September 15th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. West Pharmaceutical Services presently has an average rating of Hold and an average price target of $106.00.

West Pharmaceutical Services (NYSE WST) traded down $0.78 on Friday, reaching $100.85. 282,200 shares of the company traded hands, compared to its average volume of 366,456. West Pharmaceutical Services has a 1-year low of $76.89 and a 1-year high of $103.36. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.59 and a quick ratio of 1.87. The company has a market capitalization of $7,546.32, a PE ratio of 43.81, a price-to-earnings-growth ratio of 2.17 and a beta of 1.14.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, October 26th. The medical instruments supplier reported $0.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.53 by $0.14. The business had revenue of $398.20 million during the quarter, compared to analysts’ expectations of $386.02 million. West Pharmaceutical Services had a net margin of 12.12% and a return on equity of 14.47%. West Pharmaceutical Services’s revenue was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.53 earnings per share. sell-side analysts anticipate that West Pharmaceutical Services will post 2.76 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was originally published by BBNS and is the sole property of of BBNS. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://baseballnewssource.com/markets/west-pharmaceutical-services-inc-wst-pt-raised-to-112-00/1740065.html.

A number of large investors have recently added to or reduced their stakes in WST. Acrospire Investment Management LLC acquired a new stake in West Pharmaceutical Services during the 2nd quarter valued at approximately $113,000. Citigroup Inc. grew its position in shares of West Pharmaceutical Services by 95.1% during the 2nd quarter. Citigroup Inc. now owns 1,569 shares of the medical instruments supplier’s stock worth $148,000 after buying an additional 765 shares during the period. Wolverine Trading LLC acquired a new stake in shares of West Pharmaceutical Services during the 2nd quarter worth approximately $200,000. Nomura Holdings Inc. acquired a new stake in shares of West Pharmaceutical Services during the 2nd quarter worth approximately $201,000. Finally, Grandfield & Dodd LLC acquired a new stake in shares of West Pharmaceutical Services during the 3rd quarter worth approximately $201,000. 91.02% of the stock is owned by institutional investors and hedge funds.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Analyst Recommendations for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.